UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

Journal of the American College of Cardiology, 2010-09, Vol.56 (14), p.1079-1088

2010

Volltextzugriff (PDF)

Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser

Expert opinion on biological therapy, 2016-05, Vol.16 (5), p.723-733

2016

Volltextzugriff (PDF)

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

The Lancet (British edition), 2009-02, Vol.373 (9664), p.649-658

2009

Volltextzugriff (PDF)

Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice

Journal of cardiovascular pharmacology, 2009-01, Vol.53 (1), p.60-65

2009

Volltextzugriff (PDF)

Sa1636 NON-INVASIVE TESTING IN CHRONIC HEPATITIS D VIRUS (HDV) INFECTION: WHAT WORKS BEST TO RULE OUT CIRRHOSIS?

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1607-S-1608

2024

Volltextzugriff (PDF)

WED-407 Characterization of hepatitis D virus RNA and hepatitis B surface antigen kinetics during pegylated interferon-alphamonotherapy: The D-LIVR study

Journal of hepatology, 2024-06, Vol.80, p.S800-S801

2024

Volltextzugriff (PDF)

WED-382 Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study

Journal of hepatology, 2024-06, Vol.80, p.S814-S814

2024

Volltextzugriff (PDF)

Early Treatment with Pegylated Interferon Lambda for Covid-19

The New England journal of medicine, 2023-02, Vol.388 (6), p.518-528

2023

Volltextzugriff (PDF)

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease

European heart journal, 2011-04, Vol.32 (8), p.999-1005

2011

Volltextzugriff (PDF)

Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy

Rheumatology (Oxford, England), 2014-05, Vol.53 (5), p.957-958

2014

Volltextzugriff (PDF)

Varespladib methyl in cardiovascular disease

Expert opinion on investigational drugs, 2010-10, Vol.19 (10), p.1245-1255

2010

Volltextzugriff (PDF)

EFFECTS OF VARESPLADIB METHYL ON BIOMARKERS AND MAJOR CARDIOVASCULAR EVENTS IN ACUTE CORONARY SYNDROME PATIENTS

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A114.E1063-A114.E1063

2010

Volltextzugriff (PDF)

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial

Cardiovascular drugs and therapy, 2012-02, Vol.26 (1), p.71-75

2012

Volltextzugriff (PDF)

Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

Cardiovascular drugs and therapy, 2011-12, Vol.25 (6), p.539-544

2011

Volltextzugriff (PDF)

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A^sub 2^ (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

The Lancet (British edition), 2009-02, Vol.373 (9664), p.649

2009

Volltextzugriff (PDF)

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A 2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

The Lancet (British edition), 2009, Vol.373 (9664), p.649-658

2009

Volltextzugriff (PDF)

Inhibition of Secretory Phospholipase A^sub 2^ in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial

Cardiovascular drugs and therapy, 2012-02, Vol.26 (1), p.71

2012

Volltextzugriff (PDF)

Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial

Cardiovascular drugs and therapy, 2012-02, Vol.26 (1), p.71-75

2012

Volltextzugriff (PDF)

Leg ulcer assessment by doppler ultrasound: This article discusses the cause of leg ulcers and their assessment by Doppler ultrasound in rder to assist nurses in expanding their scope f professional

Nursing standard, 1997-07, Vol.11 (43), p.49-56

Hislop, Colin

1997

Volltextzugriff (PDF)

Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy

Rheumatology (Oxford, England), 2014, Vol.53 (5), p.957-958

2014

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(30)
Berichte
(1)

Sprache

Englisch
(31)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(13)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Female
(9)
Male
(9)
Biological And Medical Sciences
(6)
Double-Blind Method
(6)
Medical Sciences
(6)
Middle Aged
(6)
Treatment Outcome
(6)
Phospholipases A2, Secretory - Antagonists & Inhibitors
(5)
Aged
(4)
Cardiology
(4)
Cardiology. Vascular System
(4)
Coronary Heart Disease
(4)
Heart
(4)
Acetates - Administration & Dosage
(3)
Acetates - Therapeutic Use
(3)
Acute Coronary Syndrome - Drug Therapy
(3)
Adult
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice

Sa1636 NON-INVASIVE TESTING IN CHRONIC HEPATITIS D VIRUS (HDV) INFECTION: WHAT WORKS BEST TO RULE OUT CIRRHOSIS?

WED-407 Characterization of hepatitis D virus RNA and hepatitis B surface antigen kinetics during pegylated interferon-alphamonotherapy: The D-LIVR study

WED-382 Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study

Early Treatment with Pegylated Interferon Lambda for Covid-19

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta

GS-012 - Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease

Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy

Varespladib methyl in cardiovascular disease

EFFECTS OF VARESPLADIB METHYL ON BIOMARKERS AND MAJOR CARDIOVASCULAR EVENTS IN ACUTE CORONARY SYNDROME PATIENTS

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial

Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A^sub 2^ (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A 2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Inhibition of Secretory Phospholipase A^sub 2^ in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial

Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial

Leg ulcer assessment by doppler ultrasound: This article discusses the cause of leg ulcers and their assessment by Doppler ultrasound in rder to assist nurses in expanding their scope f professional

Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy

Peginterferon-Lambda for the Treatment of COVID-19 in Outpatients

Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort

Suchergebnisse filtern